Uveitis (Posterior) Blog

Allergan Receives FDA Approval for Ozurdex as Treatment Option for Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Posted 29 Sep 2010 by Drugs.com

IRVINE, Calif.--(BUSINESS WIRE)--Sep 24, 2010 - Allergan, Inc. today announced that the United States Food and Drug Administration (FDA) has approved Ozurdex (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye. Uveitis is characterized by inflammation of the eye's uvea, which is the middle vascular layer consisting of the iris (anterior), ciliary body (intermediate) and choroid (posterior). Uveitis of the anterior (front) of the uvea is more common and typically does not lead to vision impairment;1 while posterior uveitis (back of the eye) is associated with more severe outcomes that can include blindness, cataracts, secondary glaucoma and macular abnormalities.2 Posterior uveitis is the cause of 10 to 15 percent of cases of blindness in the United States.3 Ozurdex is a biodegradable ... Read more

Related support groups: Uveitis, Ozurdex, Uveitis (Posterior)